Coadministration of Anti-Viral Monoclonal Antibodies With Routine Pediatric Vaccines and Implications for Nirsevimab Use: A White Paper

被引:13
作者
Esposito, Susanna [1 ]
Abu-Raya, Bahaa [2 ]
Bonanni, Paolo [3 ]
Cahn-Sellem, Fabianne [4 ]
Flanagan, Katie L. [5 ,6 ,7 ,8 ]
Martinon Torres, Federico [9 ,10 ]
Mejias, Asuncion [11 ,12 ]
Nadel, Simon [13 ]
Safadi, Marco A. P. [14 ]
Simon, Arne [15 ]
机构
[1] Univ Parma, Univ Hosp, Dept Med & Surg, Pediat Clin, Parma, Italy
[2] Univ British Columbia, Dept Pediat, Vancouver, BC, Canada
[3] Univ Florence, Specializat Med Sch Hyg, Dept Hlth Sci, Florence, Italy
[4] Assoc Francaise Pediatrie Ambulatoire AFPA, Paris, France
[5] Launceston Gen Hosp, Tasmanian Vaccine Trial Ctr, Launceston, Tas, Australia
[6] Univ Tasmania, Sch Med, Launceston, Tas, Australia
[7] Monash Univ, Dept Pathol & Immunol, Melbourne, Vic, Australia
[8] Royal Melbourne Inst Technol RMIT Univ, Sch Hlth & Biomed Sci, Melbourne, Vic, Australia
[9] Univ Santiago Compostela, Translat Pediat & Infect Dis Pediat Dept, Hosp Clin, Santiago De Compostela, Spain
[10] Univ Santiago, Inst Investigac Sanitaria Santiago Comp, Genet Vaccines & Pediat Res Grp, Santiago De Compostela, Spain
[11] Ohio State Univ, Div Infect Dis, Ctr Vaccines & Immun, Nationwide Childrens Hosp,Dept Pediat,Coll Med, Columbus, OH USA
[12] Univ Malaga, Malaga Med Sch, Dept Pediat & Pharmacol, Malaga, Spain
[13] St Marys Hosp, London, England
[14] Santa Casa Sao Paulo Sch Med Sci, Dept Pediat, Sao Paulo, Brazil
[15] Klin Padiatr Onkol & Hamatol Univ Saarlandes, Homburg, Germany
来源
FRONTIERS IN IMMUNOLOGY | 2021年 / 12卷
关键词
monoclonal antibodies; nirsevimab; palivizumab; vaccine; RSV; RESPIRATORY SYNCYTIAL VIRUS; DIPHTHERIA-TETANUS-PERTUSSIS; MUMPS-RUBELLA VACCINE; YOUNG-CHILDREN; REDUCES HOSPITALIZATION; IMMUNIZATION PRACTICES; MATERNAL IMMUNIZATION; ADVISORY-COMMITTEE; CONJUGATE VACCINE; INFLUENZA VACCINE;
D O I
10.3389/fimmu.2021.708939
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Routine childhood vaccinations are key for the protection of children from a variety of serious and potentially fatal diseases. Current pediatric vaccine schedules mainly cover active vaccines. Active vaccination in infants is a highly effective approach against several infectious diseases; however, thus far, for some important viral pathogens, including respiratory syncytial virus (RSV), vaccine development and license by healthcare authorities have not been accomplished. Nirsevimab is a human-derived, highly potent monoclonal antibody (mAb) with an extended half-life for RSV prophylaxis in all infants. In this manuscript, we consider the potential implications for the introduction of an anti-viral mAb, such as nirsevimab, into the routine pediatric vaccine schedule, as well as considerations for coadministration. Specifically, we present evidence on the general mechanism of action of anti-viral mAbs and experience with palivizumab, the only approved mAb for the prevention of RSV infection in preterm infants, infants with chronic lung disease of prematurity and certain infants with hemodynamically significant heart disease. Palivizumab has been used for over two decades in infants who also receive routine vaccinations without any alerts concerning the safety and efficacy of coadministration. Immunization guidelines (Advisory Committee on Immunization Practices, Joint Committee on Vaccination and Immunization, National Advisory Committee on Immunization, Centers for Disease Control and Prevention, American Academy of Pediatrics, The Association of the Scientific Medical Societies in Germany) support coadministration of palivizumab with routine pediatric vaccines, noting that immunobiologics, such as palivizumab, do not interfere with the immune response to licensed live or inactivated active vaccines. Based on the mechanism of action of the new generation of anti-viral mAbs, such as nirsevimab, which is highly specific targeting viral antigenic sites, it is unlikely that it could interfere with the immune response to other vaccines. Taken together, we anticipate that nirsevimab could be concomitantly administered to infants with routine pediatric vaccines during the same clinic visit.
引用
收藏
页数:10
相关论文
共 88 条
[1]  
AbbVie, SYN SMPC
[2]   The effect of timing of maternal tetanus, diphtheria, and acellular pertussis (Tdap) immunization during pregnancy on newborn pertussis antibody levels - A prospective study [J].
Abu Raya, Bahaa ;
Srugo, Isaac ;
Kessel, Aharon ;
Peterman, Michael ;
Bader, David ;
Gonen, Ron ;
Bamberger, Ellen .
VACCINE, 2014, 32 (44) :5787-5793
[3]   Global Perspectives on Immunization During Pregnancy and Priorities for Future Research and Development: An International Consensus Statement [J].
Abu-Raya, Bahaa ;
Maertens, Kirsten ;
Edwards, Kathryn M. ;
Omer, Saad B. ;
Englund, Janet A. ;
Flanagan, Katie L. ;
Snape, Matthew D. ;
Amirthalingam, Gayatri ;
Leuridan, Elke ;
Van Damme, Pierre ;
Papaevangelou, Vana ;
Launay, Odile ;
Dagan, Ron ;
Campins, Magda ;
Cavaliere, Anna Franca ;
Frusca, Tiziana ;
Guidi, Sofia ;
O'Ryan, Miguel ;
Heininger, Ulrich ;
Tan, Tina ;
Alsuwaidi, Ahmed R. ;
Safadi, Marco. A. ;
Vilca, Luz M. ;
Wanlapakorn, Nasamon ;
Madhi, Shabir A. ;
Giles, Michelle L. ;
Prymula, Roman ;
Ladhani, Shamez ;
Martinon-Torres, Federico ;
Tan, Litjen ;
Michelin, Lessandra ;
Scambia, Giovanni ;
Principi, Nicola ;
Esposito, Susanna .
FRONTIERS IN IMMUNOLOGY, 2020, 11
[4]   Interference Between Respiratory Syncytial Virus and Human Rhinovirus Infection in Infancy [J].
Achten, Niek B. ;
Wu, Pingsheng ;
Bont, Louis ;
Blanken, Maarten O. ;
Gebretsadik, Tebeb ;
Chappell, James D. ;
Wang, Li ;
Yu, Chang ;
Larkin, Emma K. ;
Carroll, Kecia N. ;
Anderson, Larry J. ;
Moore, Martin L. ;
Sloan, Chantel D. ;
Hartert, Tina V. .
JOURNAL OF INFECTIOUS DISEASES, 2017, 215 (07) :1102-1106
[5]  
Advisory Committee on Immunization Practices, TIM SPAC IMM
[6]  
Advisory Committee on Immunization Practices, GUID VACC PREGN WOM
[7]  
Advisory Committee on Immunization Practices. Altered Immunocompetence, GEN BEST PRACTICE GU
[8]  
American Academy of Pediatrics, RED BOOK SIM ADM MUL
[9]  
Anonymous, 2011, Morbidity and Mortality Weekly Report, V60, P1391
[10]  
[Anonymous], A study to evaluate the safety and efficacy of zoledronic acid in the prevention or delaying of bone metastasis in patients with stage IIIA and IIIB non-small cell lung cancer